What is Pf-08046037 used for?

Pf-08046037 is indicated for Indication not found, Indication not found.

Who makes Pf-08046037?

Pf-08046037 is developed by Pfizer.

What development phase is Pf-08046037 in?

Pf-08046037 is FDA-approved (marketed).

What is the generic name of Pf-08046037?

pf-08046037 is the generic (nonproprietary) name of Pf-08046037.

Last reviewed 2026-04-20 · How we verify

Pf-08046037 (pf-08046037)

Pfizer · FDA-approved active Quality 22/100

PF-08046037 is a marketed drug by Pfizer Inc. It is a small molecule with a mechanism of action not specified. The drug has no key indications found. It has 1 trial and 0 publications. The commercial significance of PF-08046037 is $63.6B. There are no pipeline developments mentioned.

At a glance

Generic name	pf-08046037
Sponsor	Pfizer
Drug class	Unknown
Target	Unknown
Therapeutic area	Other
Phase	FDA-approved

Approved indications

Indication not found
Indication not found

Common side effects

No common side effects on file.

Drug interactions

Warfarin
Aspirin
Pentobarbital
Phenobarbital
Rivaroxaban
Apixaban
Dabigatran
Clopidogrel
Ticagrelor
Prasugrel
Esomeprazole
Omeprazole

Key clinical trials

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pf-08046037 CI brief — competitive landscape report
Pf-08046037 updates RSS · CI watch RSS
Pfizer portfolio CI